Business Insights

Measuring the COVID Effect on Clinical Trials

June 27, 2022

Measuring the
As the world begins its transition into a postpandemic existence, it becomes possible to look back on the past two years and begin to quantify the effects that COVID-19 has brought.

Spotlight

Pharma intelligence | informa

From drug and device discovery and development to regulatory approval, drug reimbursement to lifecycle management – you need to make smart decisions that give you an advantage in a fast changing market.

OTHER WHITEPAPERS
news image

Achieving diversity, equity and inclusion in clinical trials

whitePaper | April 26, 2022

The prevalence of communicable and non-communicable diseases are increasing worldwide, placing considerable demand on public health systems and driving a necessity to develop more effective targeted therapies.

Read More
news image

The convergence of the pharmaceutical and medicaldevices industries

whitePaper | May 26, 2022

The medical device and pharmaceutical industries each share in a mission to improve health outcomes, from prevention to intervention. As a result of this shared mission, integration and overlap between these two industries has been taking place for decades.

Read More
news image

Three Challenges Facing Study Start Up and the Low-Code Solution

whitePaper | December 22, 2022

The life sciences industry has been exploring ways to accelerate the study start up process for well over a decade. The industry has long understood the value behind faster clinical trials: the sooner clinical trial results can be delivered to agencies, the sooner a new treatment can be available for patients.

Read More
news image

Understanding Net Pharmaceutical Expenditure Dynamics in Europe

whitePaper | April 12, 2022

The level of pharmaceutical expenditure is closely watched and often commented upon, but the composition of that expenditure and its dynamics are not as well understood.

Read More
news image

Using High Throughput SPR to Explore the Full Kinetic and Epitope Diversity of Large Antibody Libraries

whitePaper | February 24, 2023

A new way of thinking and working has evolved for the discovery of therapeutic antibodies. Until recently, large numbers of antibodies were generated, only for a relatively small fraction to be sampled and engineered for further lead generation.

Read More
news image

National Council for Prescription Drug Programs

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

Read More

Spotlight

Pharma intelligence | informa

From drug and device discovery and development to regulatory approval, drug reimbursement to lifecycle management – you need to make smart decisions that give you an advantage in a fast changing market.

Events